Journal article · 2022 · Open access
Covid-19: FDA authorises pharmacists to prescribe Paxlovid
BMJ, 378, o1695 · Published 8 July 2022 · DOI 10.1136/bmj.o1695
In brief
“Covid-19: FDA authorises pharmacists to prescribe Paxlovid” is a 2022 journal article by Janice Hopkins Tanne, published in BMJ. OpenAlex counts 30 citations as of 20 November 2026, which puts it in the top 3% of works published in 2022 by citations. It is open access: the full text is free to read at BMJ.
- Citations
- 30
- Most cited in
- 2023 (9)
- Field-weighted impact
- 3.54
- Authors
- 1
Abstract
Background NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. Methods The phase 2 component of our randomized, placebo-controlled, phase 1-2 trial was designed to identify which dosing regimen of NVX-CoV2373 should move forward into late phase studies in younger (18-59 years) and older (60-84 years) participants and was based on immunogenicity and safety data through day 35 (14 days after the second dose). Participants were randomly assigned to receive either one or two intramuscular doses of 5-µg or 25-µg NVX-CoV2373 or placebo, 21 days apart. Primary endpoints were immunoglobulin G (IgG) anti-spike protein response, 7-day solicited reactogenicity, and unsolicited adverse events. A key secondary endpoint was wild-type virus neutralizing antibody response. Results After randomization, approximately 250 participants each were assigned to one of four vaccine groups or placebo. Of these, approximately 45% were older participants. Reactogenicity was predominantly mild to moderate in severity and of short duration (median <3 days) after first and second vaccination with NVX-CoV2373, with higher frequencies and intensity after second vaccination and with the higher dose, and occurred less frequently and was of lower intensity in older participants. The two-dose regimen of 5-µg NVX-CoV2373 induced robust geometric mean titer (GMT) IgG anti-spike protein (65,019 and 28,137 EU/mL) and wild-type virus neutralizing antibody (2201 and 981 titers) responses in younger and older participants, respectively, with seroconversion rates of 100% in both age groups. Neutralizing antibody responses exceeded those seen in convalescent sera for both age groups. Conclusions The study confirmed that the two-dose regimen of 5-µg NVX-CoV2373 is highly immunogenic and well tolerated in both younger and older participants. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number: NCT04368988).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Tanne, J. H. (2022). Covid-19: FDA authorises pharmacists to prescribe Paxlovid. BMJ, 378, o1695. https://doi.org/10.1136/bmj.o1695
MLA 9
Tanne, Janice Hopkins. “Covid-19: FDA authorises pharmacists to prescribe Paxlovid.” BMJ, vol. 378, 2022, p. o1695. https://doi.org/10.1136/bmj.o1695.
Chicago
Tanne, Janice Hopkins. 2022. “Covid-19: FDA authorises pharmacists to prescribe Paxlovid.” BMJ 378: o1695. https://doi.org/10.1136/bmj.o1695.
Harvard
Tanne, J. H. (2022) ‘Covid-19: FDA authorises pharmacists to prescribe Paxlovid’, BMJ, 378, p. o1695. doi:10.1136/bmj.o1695.
IEEE
J. H. Tanne, “Covid-19: FDA authorises pharmacists to prescribe Paxlovid,” BMJ, vol. 378, p. o1695, 2022, doi: 10.1136/bmj.o1695.
BibTeX
@article{tanne2022covid,
title = {{Covid-19: FDA authorises pharmacists to prescribe Paxlovid}},
author = {Tanne, Janice Hopkins},
journal = {BMJ},
year = {2022},
volume = {378},
pages = {o1695},
doi = {10.1136/bmj.o1695},
url = {https://doi.org/10.1136/bmj.o1695}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2022 | 7 | |
| 2023 | 9 | |
| 2024 | 9 | |
| 2025 | 5 |
Its field-weighted citation impact is 3.54: it has been cited 3.54 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- COVID-19 pandemic
- nirmatrelvir/ritonavir
- FDA authorization
- SARS-CoV-2
- NVX-CoV2373
- nanoparticle vaccine
- immunogenicity
- neutralizing antibodies
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Tanne, J. H. (2022). Covid-19: FDA authorises pharmacists to prescribe Paxlovid. BMJ, 378, o1695. https://doi.org/10.1136/bmj.o1695
How many times has this paper been cited?
30 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at BMJ: sign in and open the PDF from this page.
Who wrote this paper?
Janice Hopkins Tanne.
What is the DOI of this paper?
10.1136/bmj.o1695, permanently at https://doi.org/10.1136/bmj.o1695. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.